Chicago, Illinois – The Society of Thoracic Surgeons (STS) has developed and launched a new risk calculator to estimate the risk of mitral valve repair for patients with mitral valve prolapse and degenerative primary mitral regurgitation, or primary MR.

Feb 10, 2023
Dr. Molena shares how her medical journey brought her to the United States—which required repeating much of her European training—and the importance of finding a community of supporters at each step.
1 hr. 15 min.

Data analyses demonstrate that new downgraded recommendations for coronary artery bypass grafting—largely based on the ISCHEMIA trial—may result in undertreatment and complications for patients with multiple blockages

Jan 23, 2023

STS Distinguished Service Award recognizes those who advance the Society and specialty

 

Jan 23, 2023

Washington, DC surgeon will emphasize long-term outcomes and value of surgery

 

SAN DIEGO (January 23, 2023) – Cardiothoracic surgeon Thomas E. MacGillivray, MD, from MedStar Health, was elected President of The Society of Thoracic Surgeons at STS 2023 during the Society’s Business Meeting.

Jan 23, 2023
STS 2023, SAN DIEGO — Patients who undergo lobectomy for primary incidence of lung cancer often die from the same cancer recurrence, prompting researchers from Massachusetts General Hospital in Boston to advocate for adjuvant therapies at the time of surgery or following procedures. Research coordinator Alexandra Potter, BSE, presented “Incidence, Timing and Causes of Death Among Patients Who Underwent Lobectomy for Stage IA Lung Cancer in the National Lung Screening Trial (NLST),” an analysis of long-term survival of patients from the National Lung Screening Trial.  The randomized NLST included 53,454 patients. The team at Massachusetts General delved into the NLST data and developed a cohort of 433 patients whose cancers were identified by low-dose computed tomography or Xray and met other study inclusion criteria. They found that: ·       Five-year cancer-specific survival was 80%, 10-year was 70%. ·       Five-year overall survival was 72%, 10-year overall survival was 55%. ·       Five-year overall survival for patients under age 65 at time of diagnosis was 79% and 10-year overall survival was 62%. ·       Five-year overall survival for patients 65 and older at time of diagnosis was 62% and 10-year overall survival was 48% . ·       The leading cause of death for all patients in the cohort was lung cancer, either primary or at recurrence, accounting for 59% of all deaths. The longer patients lived following resection surgery, the more likely they were to die from other causes—the top ones being heart disease, COPD, and other types of cancers. “These findings highlight the importance of developing strategies to reduce the risk of lung cancer death among early-stage lung cancer patients undergoing surgery,” Potter said. This includes patients at high risk for lung cancer recurrence. Potter offered several suggestions: identifying remaining tumor cells in the blood post-surgery, which may indicate increased risk for cancer recurrence. These patients may benefit from adjuvant therapies.
Jan 22, 2023
2 min read
STS 2023, SAN DIEGO — The best practices for tricuspid valve surgery gained definition Sunday at STS 2023 as experts took the first steps to end the tricuspid’s undeserved reputation as the “forgotten valve.” Qiudong (Kevin) Chen, MD, MS, research resident at Cedars-Sinai Medical Center Smidt Heart Institute in Los Angeles, California, presented the Richard E. Clark Memorial Paper, which demonstrated that: ·       For non-endocarditis-related tricuspid regurgitation (TR), isolated tricuspid valve repair is associated with a lower risk of operative mortality (in-hospital or 30-days post-operative) than valve replacement. ·       In the same population, beating heart surgery (repair or replacement) is associated with a lower risk of pacemaker implant, renal failure, and post-operative blood transfusions than surgery under cardioplegic arrest. However, no mortality benefit was identified. ·       Higher pre-operative Model for End-Stage Liver Disease (MELD) scores were associated with higher operative mortality, especially for patients with MELD scores 20 or above. Increased levels of tricuspid valve regurgitation are associated with worse survival rates, and operative mortality can be up to 11% in patients undergoing isolated surgery. Both these factors contributed to the need for this analysis on a larger population level in order to start uncovering optimal surgical strategies. Senior authors for this study were Dr. Michael Bowdish and Dr. Joanna Chikwe. Dr. Chen and his surgeon colleagues conducted their review using the STS National Database™, which he called a “powerful, comprehensive tool” that allowed his team to review procedural trends and volumes from 2012 to 2019 across the US. He noted several limitations in the analysis, including lack of long-term outcomes and incomplete etiology. From the Adult Cardiac Surgery Database, physician-scientists initially identified 14,704 patients who underwent isolated tricuspid valve surgery and further narrowed this to 6,507 patients with non-endocarditis-related tricuspid regurgitation, who were assessed in the study. Although tricuspid regurgitation is common, the study confirmed that this disorder is extremely undertreated. Tricuspid repair and replacement remain rare surgeries nationwide: the investigators found that 93% of US medical centers performed five or fewer of these procedures annually. A majority of procedures were conducted with patients under cardiac arrest, followed by surgeries on patients with beating hearts and a small minority performed on patients with fibrillating hearts. “I believe these findings suggest that in this patient population, tricuspid repair may be a safer option when feasible,” Dr. Chen said. He was joined by senior co-authors Michael E. Bowdish, MD, MS, Jad Malas, MD, and Amy Roach, MD, all also from Cedars-Sinai, in this study. “Surgical outcomes for isolated TR are poor, and we can do better by generating additional clinical evidence by identifying those patients with TR and operating on them early,” added James Gammie, MD, professor of surgery at Johns Hopkins Medicine, who served as discussant. Putting tricuspid regurgitation in perspective, Dr. Gammie noted that about 1.6 million people in the US have significant TR, making the disease almost as prevalent as aortic stenosis.
Jan 22, 2023
3 min read
This scientific presentation covered in this article was part of the STS 2023 session “Perspectives from Asia: Aortic Disease, Coronary Disease, and Mechanical Circulatory Support,” and is available in Annual Meeting Online. Access or purchase it here. For Asian patients with aortic disease, determining whether to take a surgical or conservative approach to treatment may depend on much more than size. “Given my particular interest in aortic surgery and participation in the recently released American College of Cardiology/American Heart Association guidelines, I was asked to try to answer this question,” said Edward P. Chen, MD, from Duke University School of Medicine in Durham, North Carolina. “As I dug deeper, I found that the answer is considerably more complicated than a simple yes or no.” In terms of comparative studies, data that can help to quantify aortic disease risk can vary significantly in populations identified as “Asian,” Dr. Chen said. Even as body habitus fluctuates from region to region, the risk of adverse events may be based not only on the diameter of the aorta, but also aortic diameter indexed to both body surface area and height. “As it turns out, despite what I heard occasionally when I was growing up,  Asians do not all look the same.” Environmental and cultural factors throw another wrench: A patient who is a Japanese national, for example, might have a markedly different lifestyle than an ethnically Japanese patient living in the West. “When I was a medical student, for instance, I learned there was a high incidence of gastric cancer in Japan," Dr. Chen said. "But Japanese people living in the US have more colorectal cancer, which could potentially be explained by differences in both diet and environmental conditions.” The incidence of comorbid conditions—as well as access to health care—ranges widely in patient cohorts across the globe. When Dr. Chen began researching his presentation, he reached out to Dr. Kay-Hyun Park of Seoul, Korea, president of the Asian Society for Cardiovascular and Thoracic Surgery, for an additional perspective. Dr. Park’s blunt reply: “I (and probably any Asian surgeon) cannot represent the entire ‘Asia’ and deliver the ‘Asian perspective,’ because I have no means to grasp what they are doing in the other Asian countries.” Dr. Park added, “Even in my own neighborhood in Korea, their aggressiveness is quite varied.” He went on to say that, in areas where patients might have more limited access to state-of-the-art surgical care, a surgeon might err more aggressively on the side of surgery—not knowing when they might get to see that patient again. Acknowledging the limitations and complexity at work, Dr. Chen and his coauthors aimed to design the latest guidelines to assist the clinician in making the best decisions for each patient on a case-by-case basis. The presentation was part of a session hosted jointly by STS and the Asian Society for Cardiovascular and Thoracic Surgery, “Perspectives from Asia: Aortic Disease, Coronary Disease, and Mechanical Circulatory Support,” moderated by S. Christopher Malaisrie, MD, and Wilson Y. Szeto, MD.   “Shared decision making is going to be the key here,” Dr. Chen said. “Yes, we don't actually have all the answers. But what we should do is take the data we have and try to individualize it to every patient we take care of, and not have a uniform umbrella policy. Particularly here in the United States, with the potpourri of diverse ethnic groups we take care of, it’s important to use the guidelines along with the data we have, the patient’s known measurable anatomic factors as well as lifestyle considerations, and one’s own experience and clinical judgment to make the best decision possible for the patient.”
Jan 22, 2023
3 min read
STS 2023 DAY 3 — Today is your chance to give input as cardiothoracic surgeons work to establish vital guidelines in pediatric surgery for congenital heart defects. Several of the nation's foremost surgeons will present their studies to date that will be the foundation for STS practice guidelines and consensus documents.  On Monday, January 23 at 11:55 a.m. PT, Jeffrey P. Jacobs, MD, a professor of surgery and pediatrics at the University of Florida in Gainesville, and Tara Karamlou, MD, MSc, from Cleveland Clinic in Ohio, will chair the highly collaborative session "It's All About the Data—Evidence Based Guidelines for Congenital Heart Surgery." These and other surgeons involved in the multi-institutional research want your feedback. This session will showcase the extensive research conducted to date by the Evidence Based Task Force for Congenital Heart Surgery and offer participants opportunities to contribute their own insights. Dr. Jacobs leads the task force, which is undertaking three projects where consensus on optimal care approaches does not exist: Strategies for Left Ventricular Recruitment in Neonates and Borderline in Left Heart Structures, chaired by Dr. Karamlou, Bahaaldin Alsoufi, Chief of Cardiothoracic Surgery at Norton’s Children’s Hospital in Louisville, Kentucky, and Eric Feins, MD, from Boston Children’s Hospital in Massachusetts. Management of Neonates and Infants with Coarctation, chaired by Elizabeth Stephens, MD, PhD from Mayo Clinic in Rochester, Minnesota, and Hani Najm, MD, from Cleveland Clinic in Ohio. Indications and Timing of Pulmonary Valve Replacement in Repaired Tetralogy of Fallot, chaired by Jennifer Nelson, MD, from Nemours Children’s Hospital in Orlando, Florida, and James St. Louis, MD, Section Chief of Pediatric and Congenital Heart Surgery from Children’s Hospital of Georgia in Augusta. "It has truly been an honor for me to observe the dedication and professionalism of these STS leaders as they pursued, with great scientific rigor, the best answers available to three very challenging clinical dilemmas," Dr. Jacobs says. "I am certain that the tremendous effort devoted to these studies will generate important knowledge that will ultimately improve the lives of many babies and children with congenital heart disease." These initiatives followed the call in 2022 by STS President John Calhoon, MD, to improve cardiothoracic surgery across the world. From there, the STS Workforce on Evidence Based Surgery created three Task Forces addressing some of the most pressing and unanswered surgical issues, including the congenital heart surgery group.    Research presented today will lead to publication of an STS Clinical Practice Guideline in The Annals of Thoracic Surgery and two STS Expert Consensus documents later this year.
Jan 22, 2023
3 min read
The J. Maxwell Chamberlain Memorial Papers and the inaugural James S. Tweddell Memorial Paper in Congenital Heart Surgery were named yesterday morning at STS 2023. “Creation of a Novel Society of Thoracic Surgeons Adult Congenital Heart Surgery Mortality Risk Model" Jennifer Nelson, MD, MSc Nemours Children’s Health, Florida “Racial Disparities in Waitlist Outcomes of Patients Listed for Lung Transplantation” Isabella Florissi Johns Hopkins University "The COVID-19 Pandemic is Associated with Increased Cardiac Surgery Mortality, FTR, and Cost across All Socioeconomic Statuses” Raymond Strobel, MD University of Virginia “Contemporary Coronary Artery Bypass Grafting versus Multivessel Percutaneous Coronary Intervention in 100,000 Matched Medicare Beneficiaries” J. Hunter Mehaffey, MD, MSc West Virginia University
Jan 22, 2023
1 min read
  An all-star panel oversaw the presentation and discussion of state-of-the-art techniques in "Robotic Cardiac Surgery Is Here to Stay."     Yesterday morning, STS Members' outstanding research and achievements were recognized with these prestigious awards: The Earl Bakken Scientific Achievement Award was established in 1999 through a grant from Medtronic, Inc., to honor individuals who have made outstanding scientific contributions that have enhanced the practice of cardiothoracic surgery and patients’ quality of life. The award was named for Medtronic co-founder Earl Bakken. Among numerous other achievements, Bakken developed the first wearable artificial pacemaker. 2023 Winner:  Bartley P. Griffith, MD University of Maryland School of Medicine Selected by the STS President, this award recognizes an outstanding scientific abstract by a lead author who is either a resident or a surgeon 5 years or less in practice. 2023 Winner:  Elizabeth H. Stephens, MD, PhD Mayo Clinic The Benson R. Wilcox Resident Award, offered by the Thoracic Surgery Directors Association, recognizes an exceptional scientific abstract presented by a cardiothoracic surgery resident. 2023 Winner:  Andrea L. Axtell, MD, MPH Massachusetts General Hospital   In his President's Address, "Three Score and More," Dr. John Calhoon related the decades of experience that shaped his values as a teacher and a learner, and on the importance of employing data to improve patient care and outcomes.     Hands-on experiences brought colleagues together for invaluable advice from veteran surgeons, demonstrations of new devices and techniques, and the thrill of working as a team.   After their last competitive round was stymied by hurricane conditions in Florida, the finalists for the CT Surgery Residents Showdown finally squared off for the last time yesterday at STS 2023.  
Jan 22, 2023
2 min read

STS award honors game-changers in cardiothoracic surgery research

Jan 22, 2023